Tivantinib is an inhibitor of MET and GSK-3α/β that exhibits anticancer chemotherapeutic activity. Tivantinib inhibits proliferation of non-small cell lung cancer (NSCLC) cells and is currently undergoing clinical trials, showing improvements in time to progression and overall survival in the treatment of hepatocellular carcinoma.
| Cas No. | 1000873-98-2, 905854-02-6 |
|---|---|
| Purity | ≥98% |
| Formula | C23H19N3O2 |
| Formula Wt. | 369.42 |
| Synonym | ARQ-197 |
| Appearance | Light pink powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | T3584 Info Sheet PDF |
|---|
Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8. PMID: 24215125.
Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol. 2013 Feb;9(2):153-65. PMID: 23414466.
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010 Jun;13(6):404-14. PMID: 20506063.
